Hematologic Malignancy
Plasma Cell Neoplasm
CI-CAN-00006438Explore in graph →
HematologicNon-malignant831 active trials25 approved drugs26 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006438Explore in graph →
Clinical trials
3,420 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01296503 | Thalidomide Plus Dexamethasone as Maintenance Therapy for Multiple Myeloma | completed | Phase 3 | 213 | Grupo de Estudos Multicentricos em Onco-HematologiaNETWORK | 1 | Feb 15, 2011 | clinicaltrials |
| NCT00185653 | Mixed Chimera Allogeneic Transplantation From Matched Unrelated Donors For The Treatment Of Multiple Myeloma | completed | N/A | 40 | Stanford UniversityOTHER | 1 | Feb 14, 2011 | clinicaltrials |
| NCT00602511 | Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma | completed | Phase 3 | 300 | Nordic Myeloma Study GroupOTHER | 3 | Feb 9, 2011 | clinicaltrials |
| NCT00050687 | Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies | terminated | Phase 1 / Phase 2 | — | Titan PharmaceuticalsINDUSTRY | 1 | Jan 28, 2011 | clinicaltrials |
| NCT00388635 | Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients. | completed | Phase 1 / Phase 2 | 60 | PETHEMA FoundationOTHER | 1 | Jan 11, 2011 | clinicaltrials |
| NCT01274403 | A Randomized Study With Oral Melphalan + Prednisone (MP) Versus Melphalan, + Prednisone + Thalidomide (MPT) for Newly Diagnosesd Elderly Patients With Multiple Myeloma | completed | Phase 2 | 130 | Gruppo Italiano Studio LinfomiOTHER | 1 | Jan 11, 2011 | clinicaltrials |
| NCT01250808 | Technology Platform and System Construction of Clinical Evaluation Studies on New Drugs of Hematological Malignancy | available | — | — | Peking UniversityOTHER | 1 | Dec 1, 2010 | clinicaltrials |
| NCT01249690 | Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma | unknown | Phase 4 | 100 | Second Military Medical UniversityOTHER | 1 | Nov 30, 2010 | clinicaltrials |
| NCT00162500 | A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies | withdrawn | Phase 2 | 15 | Hadassah Medical OrganizationOTHER | 1 | Nov 10, 2010 | clinicaltrials |
| NCT01234129 | Stem Cell Transplant and Zoledronic Acid Improve Outcome in Previously Untreated Patients With Multiple Myeloma | completed | — | 320 | Instituto Mexicano del Seguro SocialOTHER_GOV | 1 | Nov 4, 2010 | clinicaltrials |
| NCT01233895 | Study of AVE1642 Anti-IGF1R Monoclonal Antibody in Patients With Advanced Multiple Myeloma | completed | Phase 1 | 26 | SanofiINDUSTRY | 2 | Nov 3, 2010 | clinicaltrials |
| NCT00935597 | Host Dendritic Cells in Allograft Patients | unknown | Phase 1 | 25 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Oct 29, 2010 | clinicaltrials |
| NCT00095680 | Extension Study of the Efficacy and Safety of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma | completed | Phase 2 | 30 | Scios, Inc.INDUSTRY | 0 | Oct 22, 2010 | clinicaltrials |
| NCT00689000 | Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM) | completed | Phase 1 / Phase 2 | 57 | Chroma TherapeuticsINDUSTRY | 1 | Oct 22, 2010 | clinicaltrials |
| NCT00087867 | Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma | completed | Phase 2 | 62 | Scios, Inc.INDUSTRY | 0 | Oct 18, 2010 | clinicaltrials |
| NCT00186238 | High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma | completed | Phase 2 | 300 | Stanford UniversityOTHER | 1 | Sep 14, 2010 | clinicaltrials |
| NCT01177371 | High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma | completed | Phase 2 | 13 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 9, 2010 | clinicaltrials |
| NCT00083460 | Study of Combination PS-341 and Thalidomide in Multiple Myeloma | completed | Phase 1 | 86 | University of ArkansasOTHER | 1 | Aug 2, 2010 | clinicaltrials |
| NCT01171443 | The Pathophysiology of Bortezomib Induced Peripheral Neuropathy(BIPN) | unknown | — | 30 | Wolfson Medical CenterOTHER_GOV | 1 | Jul 28, 2010 | clinicaltrials |
| NCT00794261 | Stem Cell Mobilization With Pegfilgrastim in Lymphoma and Myeloma(PALM) | completed | Phase 2 | 150 | Centre Leon BerardOTHER | 1 | Jul 8, 2010 | clinicaltrials |
| NCT00083538 | Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally | completed | Phase 2 | 40 | University of ArkansasOTHER | 1 | Jul 7, 2010 | clinicaltrials |
| NCT00083408 | Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide | completed | Phase 2 | 20 | University of ArkansasOTHER | 1 | Jul 5, 2010 | clinicaltrials |
| NCT00081757 | An Open Protocol for the Compassionate Use of Thalidomide | completed | Phase 1 / Phase 2 | 250 | University of ArkansasOTHER | 1 | Jul 2, 2010 | clinicaltrials |
| NCT00083577 | Anti-Angiogenesis Therapy Using Thalidomide in Multiple Myeloma | completed | Phase 2 | 250 | University of ArkansasOTHER | 1 | Jul 2, 2010 | clinicaltrials |
| NCT00083681 | DCEP in Combination With Thalidomide as Salvage Therapy for Post Transplantation Relapse | completed | Phase 2 | 180 | University of ArkansasOTHER | 1 | Jul 2, 2010 | clinicaltrials |
| NCT00083876 | D.T. PACE Versus High Dose Melphalan and Autologous Transplant in Patients With Previously Treated Multiple Myeloma | completed | Phase 3 | 500 | University of ArkansasOTHER | 1 | Jul 2, 2010 | clinicaltrials |
| NCT00083902 | Dexamethasone or Dexamethasone in Combination With Thalidomide as Salvage Therapy | completed | Phase 2 | 190 | University of ArkansasOTHER | 1 | Jul 2, 2010 | clinicaltrials |
| NCT00093028 | Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II | completed | Phase 3 | 315 | University of ArkansasOTHER | 1 | Jul 2, 2010 | clinicaltrials |
| NCT00193557 | Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma | completed | Phase 2 | 40 | SCRI Development Innovations, LLCOTHER | 1 | Jun 29, 2010 | clinicaltrials |
| NCT00417911 | Efficacy of Bortezomib Consolidation After High-dose Melphalan With Stem Cell Support in Myeloma Patients | completed | Phase 3 | 400 | Nordic Myeloma Study GroupOTHER | 5 | Jun 22, 2010 | clinicaltrials |
| NCT00508209 | Bortezomib and High-dose Melphalan at Myeloma Relapse | unknown | Phase 2 | 50 | Nordic Myeloma Study GroupOTHER | 3 | Jun 22, 2010 | clinicaltrials |
| NCT01016548 | Evaluation of Influenza H1N1 Vaccine in Adults With Lymphoid Malignancies on Chemotherapy | completed | Phase 3 | 42 | University Health Network, TorontoOTHER | 1 | Jun 4, 2010 | clinicaltrials |
| NCT00275262 | A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation | terminated | Phase 2 | 25 | AbbottINDUSTRY | 1 | May 6, 2010 | clinicaltrials |
| NCT00222053 | IFM 99-02 Thalidomide in Myeloma | completed | Phase 3 | 800 | University Hospital, ToulouseOTHER | 1 | Apr 2, 2010 | clinicaltrials |
| NCT00179647 | Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma | completed | Phase 3 | 1,913 | Celgene CorporationINDUSTRY | 2 | Mar 16, 2010 | clinicaltrials |
| NCT01085058 | Predictive Value of the "Cytocapacity Test" Patients With Lymphoproliferative Diseases and High-dose Therapy(CU01) | completed | Phase 2 / Phase 3 | 169 | WiSP Wissenschaftlicher Service Pharma GmbHOTHER | 0 | Mar 11, 2010 | clinicaltrials |
| NCT00304590 | Study of XL999 in Patients With Multiple Myeloma | terminated | Phase 2 | 4 | Symphony Evolution, Inc.INDUSTRY | 1 | Feb 22, 2010 | clinicaltrials |
| NCT01070862 | Multiple Myeloma Treated With Thalidomide Before Autotransplant or With Conventional Chemotherapy and as Consolidation/Maintenance Treatment in Young and Elderly Patients : 3 Randomized Studies.(MAG 2002) | completed | Phase 3 | — | University Hospital, CaenOTHER | 1 | Feb 18, 2010 | clinicaltrials |
| NCT00124813 | Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in Patients With Multiple Myeloma | unknown | Phase 2 | 80 | University Hospital, BonnOTHER | 1 | Feb 2, 2010 | clinicaltrials |
| NCT00459069 | The Use of Dendritic Cell/Tumor Fusions as a Novel Tumor Vaccine in Patients With Multiple Myeloma | completed | Phase 1 | 18 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jan 12, 2010 | clinicaltrials |
| NCT00571168 | Efficacy and Safety of Aprepitant in Subjects With Multiple Myeloma During and After High-dose Chemotherapy(EmNa) | unknown | Phase 3 | 362 | Heidelberg UniversityOTHER | 1 | Jan 12, 2010 | clinicaltrials |
| NCT00229203 | A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma | completed | Phase 2 | 51 | PharmaMarINDUSTRY | 1 | Dec 24, 2009 | clinicaltrials |
| NCT00243763 | TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma | terminated | Phase 1 | 64 | NovartisINDUSTRY | 1 | Nov 23, 2009 | clinicaltrials |
| NCT00195533 | Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients | completed | — | 801 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Nov 16, 2009 | clinicaltrials |
| NCT00988312 | Dendritic Cells(DC)-Based Id Vaccination in Stage-I Myeloma | completed | Phase 1 | 9 | University Hospital Carl Gustav CarusOTHER | 1 | Oct 2, 2009 | clinicaltrials |
| NCT00051116 | A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma | completed | Phase 2 | 100 | Celgene CorporationINDUSTRY | 1 | Sep 23, 2009 | clinicaltrials |
| NCT00425347 | Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple Myeloma | completed | Phase 1 | 35 | Facet BiotechINDUSTRY | 1 | Sep 23, 2009 | clinicaltrials |
| NCT00391157 | VELCADEXA: Velcade and Dexamethasone in Multiple Myeloma | completed | Phase 2 | 40 | PETHEMA FoundationOTHER | 1 | Sep 18, 2009 | clinicaltrials |
| NCT00461747 | GEM05 for Patients With Multiple Myeloma Under 65 Years(GEM05MENOS65) | completed | Phase 3 | 390 | PETHEMA FoundationOTHER | 1 | Sep 18, 2009 | clinicaltrials |
| NCT00186316 | Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells | completed | Phase 1 / Phase 2 | 30 | Stanford UniversityOTHER | 1 | Aug 25, 2009 | clinicaltrials |
Data updated 22 days agoSource updated Feb 15, 2011source: clinicaltrials